6 February 2026 - Pendopharm announced today that Health Canada has granted market authorisation for Yorvipath (palopegteriparatide injection), a parathyroid hormone replacement therapy indicated for the treatment of chronic hypoparathyroidism in adults. Yorvipath, was developed by Ascendis Pharma.

This approval follows the exclusive distribution agreement signed in July 2024 between Pendopharm and Ascendis Pharma, under which Pendopharm is responsible for the regulatory approval and commercialisation of Yorvipath in Canada, which is already approved in the US, European Union, UK, Australia, Switzerland, Israel and Japan.

Read Pendopharm press release